Queensland Clinical Clerk/Med Student TX Decision:
Approach to the Weak and Dizzy Patient
Stroke: Prevention and Acute Management
Secondary Prevention of Ischemic Stroke with Antiplatelet Agents
When compared with placebo, stroke risk was
reduced by 18% with ASA 25 mg bid, 16% with ER
dipyridamole 200 mg bid and 37% with combination
therapy. After two years of follow-up, stroke rates were
12.5% with ASA alone, 12.7% with dipyridamole alone,
9.5% with combination therapy and 15.1% with placebo.
The results confirmed that the combination of ASA and
ER dipyridamole was significantly more effective than
either component prescribed alone for prevention of
stroke. The stroke reduction from ASA alone also
confirmed the efficacy of low dose ASA
Is acetylsalicylic acid plus dipyridamole superior to ASA alone ...
A Peer-Reviewed Bulletin for the Family Physician
Newer antiplatelet agents are also available and useful. In
one study, clopidogrel (Plavix) caused a relative risk reduction
of 8.7 percent for the combined endpoint of stroke, MI or
vascular death, compared with aspirin.38 Another study
found 24 percent reduction of secondary strokes for those
who took a combination of dipyridamole and ASA (ER-DP/
ASA) (Aggrenox).39 Dipyridamole (Persantine) alone has not
been found to be useful for stroke prevention. The American
College of Chest Physicians (ACCP) guidelines state that ASA,
clopidogrel and ER-DP/ASA are all acceptable as first-line
agents for secondary stroke prevention.40 Patients who receive
these agents while hospitalized have the best outcomes and best
adherence to their treatment schedules, as assessed at follow-up
visits with their physicians.
Aetna Pharmacy Policy decision on Antiplatelet Med Coverage---covers med:
http://www.aetna.com/products/rxmedi...elet_2007.html
Stroke Prevention Clinical Trials:
Stroke Trials Registry